Literature DB >> 10212132

Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4.

G R Pettit1, B E Toki, D L Herald, M R Boyd, E Hamel, R K Pettit, J C Chapuis.   

Abstract

The South African willow tree Combretum caffrum has yielded a number of potent cancer cell growth inhibitors. The present SAR studies of the antineoplastic agent combretastatin A-4 (1c) were focused mainly on the olefinic bridge to determine the effects on cancer cell growth and, potentially, to better define the combretastatin A-4 binding site on tubulin. The geometric trans-isomer 3a of combretastatin A-4 was converted to the (1S,2S)- and (1R,2R)-vicinal diols 4c and 4d, respectively, under Sharpless' asymmetric dihydroxylation conditions. Cancer cell line testing showed the (1S, 2S)-diol 4c to be more potent than its enantiomer 4d. Diol 4c weakly inhibited tubulin polymerization (IC50 = 22 microM, versus 1.2 microM for combretastatin A-4), while 4d was inactive (IC50 > 40 microM). Esterification of either stereoisomer at the diol and/or phenolic positions resulted in elimination of inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10212132     DOI: 10.1021/jm9807149

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells.

Authors:  Katharina Mahal; Aamir Ahmad; Seema Sethi; Marcus Resch; Ralf Ficner; Fazlul H Sarkar; Rainer Schobert; Bernhard Biersack
Journal:  Cell Oncol (Dordr)       Date:  2015-09-10       Impact factor: 6.730

2.  Combretastatin A-4 derivatives: synthesis and evaluation of 2,4,5-triaryl-1H-imidazoles as potential agents against H1299 (non-small cell lung cancer cell).

Authors:  Chih-Hua Tseng; Chi-Yi Li; Chien-Chih Chiu; Huei-Ting Hu; Chein-Hwa Han; Yeh-Long Chen; Cherng-Chyi Tzeng
Journal:  Mol Divers       Date:  2012-09-26       Impact factor: 2.943

3.  Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.

Authors:  Sonia Arora; Xin I Wang; Susan M Keenan; Christina Andaya; Qiang Zhang; Youyi Peng; William J Welsh
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

4.  Synthesis and Biological Evaluation of 3-Alkyl-1,5-Diaryl-1H-Pyrazoles as Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative Activity.

Authors:  Qile Xu; Huan Qi; Maolin Sun; Daiying Zuo; Xuewei Jiang; Zhiyong Wen; Zhiwei Wang; Yingliang Wu; Weige Zhang
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

5.  ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.

Authors:  Min Su; Jingjia Huang; Jijia Li; Xiyuan Qin; Xiaoning Tang; Fang Jin; Shali Chen; Chuanming Jiang; Zizheng Zou; Kunjian Peng; Mohammed Nuruzzaman; Jianting Zhang; Junli Luo; Suyou Liu; Zhiyong Luo
Journal:  Oncotarget       Date:  2016-04-05

6.  ZLM-7 Blocks Breast Cancer Progression by Inhibiting MDM2 via Upregulation of 14-3-3 Sigma.

Authors:  Min Wen; Zi-Zheng Zou; Tiao Luo; Xuan Li; Su-You Liu; Ji-Jia Li; Zhi-Yong Luo
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-15

Review 7.  Tubulin-interactive stilbene derivatives as anticancer agents.

Authors:  Renata Mikstacka; Tomasz Stefański; Jakub Różański
Journal:  Cell Mol Biol Lett       Date:  2013-07-01       Impact factor: 5.787

8.  New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones.

Authors:  Gjorgji Atanasov; Rusi I Rusew; Vladimir M Gelev; Christo D Chanev; Rosica Nikolova; Boris L Shivachev; Ognyan I Petrov; Margarita D Apostolova
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.